Premium
Comparable outcome between endometrioid and non‐endometrioid tumors in patients with early‐stage high‐grade endometrial cancer
Author(s) -
Reynaers E.A.E.M.,
Ezendam N.P.M.,
Pijnenborg J.M.A.
Publication year - 2015
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23871
Subject(s) - medicine , endometrial cancer , stage (stratigraphy) , clear cell , serous fluid , cancer , adjuvant therapy , oncology , hysterectomy , gynecology , carcinoma , radiology , paleontology , biology
Background Approximately 25% of endometrial cancer patients present with high‐grade tumors. Unlike the clearly defined work‐up for non‐endometrioid endometrial cancer, no consensus exists for surgical staging and adjuvant therapy in high‐grade endometrioid endometrial cancer. We compared the recurrence rate and disease‐related mortality (DRM) after treatment between endometrioid and non‐endometrioid endometrial cancer. Methods A total of 123 patients diagnosed with early‐stage high‐grade endometrial cancer at the Dutch Comprehensive Cancer Centre South (CCCS) between January 2005 and December 2011 were included. All patients underwent abdominal hysterectomy and bilateral salpingo‐oophorectomy. Patient and tumor characteristics, primary and adjuvant treatment, and outcome were analyzed. Results After a median follow‐up of 27.9 months, 27.6% (n = 34) of patients had recurrent disease. Distant recurrence rate was equal among endometrioid (14.5%), papillary serous (14.8%), and clear cell (15.4%) types. The total DRM was 15.4% (n = 19). The 5 year recurrence‐free survival was not significantly different between early‐stage high‐grade endometrioid versus non‐endometrioid endometrial cancer ( P = 0.72). Conclusion Distant recurrence and DRM was high in patients with endometrial cancer regardless of histological type, suggesting the need for different therapies in early‐stage high‐grade non‐endometrioid and endometrioid tumors. J. Surg. Oncol. 2015 111:790–794 . © 2015 Wiley Periodicals, Inc.